http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
-
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
-
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
-
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
-
Biogen (BIIB) and Ionis (IONS) Report Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
-
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
-
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
-
Biogen (BIIB) Highlights New Data on Alzheimer’s and Parkinson’s Diseases
-
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
-
Eisai, Biogen (BIIB) Injectable-At-Home Alzheimer's Drug Demonstrates Encouraging Potential
-
Reata Pharma (RETA) Stockholders Approve Merger Transaction With Biogen (BIIB)
-
SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD
-
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
-
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
-
Biogen (BIIB) to Acquire Reata Pharmaceuticals (RETA) for $172.50/Share, Approximately $7.3 Billion
-
Biogen to Acquire Reata Pharmaceuticals
-
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
-
Biogen (BIIB) Announces FDA Granted Traditional Approval for LEQEMBI
-
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
-
Biogen (BIIB) Presents New Data on SPINRAZA
-
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
-
Biogen (BIIB) Announces Board Changes
-
Biogen Announces Changes to Its Board of Directors
-
Biogen (BIIB) Announces FDA AdCom Voted Unanimously in Favor of Clinical Benefit of LEQEMBI for Treatment of Alzheimer's Disease
-
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
-
PureTech Announces Annual Results for Year Ended December 31, 2022
-
Biogen (BIIB) Announces FDA Grants Accelerated Approval for QALSODY for SOD1-ALS
-
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
-
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
-
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
-
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
-
Biogen Appoints Adam Keeney as Head of Corporate Development
-
Biogen (BIIB) and Eisai Report Publication of Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab
-
ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS
-
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
-
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
-
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
-
Biogen (BIIB) Reports Promising Phase 1b Data for BIIB080
-
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
-
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
-
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
-
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
-
Biogen (BIIB) receives favorable EUR court ruling on TECFIDERA
-
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
-
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
-
Biogen Appoints Chuck Triano as Head of Investor Relations
-
Biogen (BIIB) Announces Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Board of Directors
-
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
-
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
-
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
